Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Cyclacel Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Acute Myeloid Leukemia

Treatments: Drug: Sapacitabine, Arm B; Drug: sapacitabine, Arm F; Drug: Sapacitabine, Arm A; Drug: Sapacitabine, Arm G; Drug: Sapacitabine, Arm I; Drug: Sapacitabine, Arm C; Drug: Sapacitabine, Arm D; Drug: Sapacitabine, Arm H; Drug: sapacitabine, Arm E

Study type: Interventional

Funder types: Industry

Identifiers

NCT00590187

CYC682-06

Details and patient eligibility

About

The objective is to treat elderly AML and MDS patients with sapacitabine.

Full description

The main objective of this study is to learn which sapacitabine treatment is more likely to keep the cancer in check for at least one year in AML patients who are at least 70 years of age or older and in MDS patients who are at least 60 years of age.

Enrollment: 105 patients

Sex: All

Ages: 60+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A histologically or pathologically confirmed diagnosis of AML based on WHO classification which is previously untreated by systemic therapy or is in first relapse after achieving a complete remission to initial induction, consolidation and/or maintenance therapy or MDS with IPSS scores of intermediate -2 or higher risk risk which has been previously treated with hypomethylating agents
• Age 70 years or older for AML and 60 years or older for MDS
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Adequate renal function defined as serum creatinine equal to or less than 1.5 x upper limit of normal (ULN)
• Adequate liver function defined as total bilirubin or direct bilirubin equal to or less than 1.5 x ULN; alanine aminotransferase (ALT or SGPT) equal to or less than 2.5 x ULN (5 x ULN if tumor has affected the liver)
• Life expectancy reasonably adequate for evaluating the treatment effect
• Patient must be able to swallow capsules
• Patients must be at least 2 weeks from prior systemic therapy, radiation therapy, major surgery, or other investigational therapy, and have recovered from clinically significant toxicities of these prior treatments
• All men and women of reproductive potential must agree to practice effective contraception for 4 weeks prior to study entry, during the entire study period and for one month after the study unless documentation of infertility exists
• Ability to understand and willingness to sign the informed consent form

Exclusion criteria

• AML is of the sub-type of acute promyelocytic leukemia
• Having received more than one induction systemic therapy for AML or having received a standard dose or high dose ara-C containing regimen for MDS
• Patients with known central nervous system (CNS) involvement by leukemia
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, active cancer(s) other than AML, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Patients receiving intravenous antibiotics for infections that are under control may be included in this study
• Known to be HIV-positive

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

105 participants in 9 patient groups

A sapacitabine

Experimental group

Description:

200 mg b.i.d. x 7 days every 3-4 weeks

Treatment:

Drug: Sapacitabine, Arm A

B sapacitabine

Experimental group

Description:

300 mg b.i.d. x 7 days every 3 - 4 weeks

Treatment:

Drug: Sapacitabine, Arm B

C sapacitabine

Experimental group

Description:

400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks

Treatment:

Drug: Sapacitabine, Arm C

D sapacitabine

Experimental group

Description:

200 mg b.i.d. x 7 consecutive days every 4 weeks

Treatment:

Drug: Sapacitabine, Arm D

E sapacitabine

Experimental group

Description:

300 mg q.d. x 7 consecutive days every 4 weeks

Treatment:

Drug: sapacitabine, Arm E

F sapacitabine

Experimental group

Description:

300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks

Treatment:

Drug: sapacitabine, Arm F

G sapacitabine

Experimental group

Description:

200 mg b.i.d. x 7 consecutive days every 4 weeks

Treatment:

Drug: Sapacitabine, Arm G

H sapacitabine

Experimental group

Description:

300 mg q.d. x 7 consecutive days every 4 weeks

Treatment:

Drug: Sapacitabine, Arm H

I sapacitabine

Experimental group

Description:

100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks

Treatment:

Drug: Sapacitabine, Arm I